WO1986000892A1 - Nouveaux composes a l'activite immunisante - Google Patents

Nouveaux composes a l'activite immunisante Download PDF

Info

Publication number
WO1986000892A1
WO1986000892A1 PCT/AT1985/000019 AT8500019W WO8600892A1 WO 1986000892 A1 WO1986000892 A1 WO 1986000892A1 AT 8500019 W AT8500019 W AT 8500019W WO 8600892 A1 WO8600892 A1 WO 8600892A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compounds
bis
anthraquinone
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT1985/000019
Other languages
German (de)
English (en)
French (fr)
Inventor
Rudolf Biber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AT85903971T priority Critical patent/ATE41769T1/de
Priority to DE8585903971T priority patent/DE3569107D1/de
Publication of WO1986000892A1 publication Critical patent/WO1986000892A1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Definitions

  • the invention relates to a process for the preparation of new immunologically active compounds from the series of the anthraquinones substituted in the 2,6-position and their physiologically tolerable acid addition salts of the general formula (I)
  • R 1 and R 2 are different, in which case R 1
  • the process for the preparation of the new immunologically active compounds of the general formula (I) and their acid addition salts consists in that, in a manner known per se (e.g. according to the process of acylation using chloroacetyl chloride, described in the manual of the biological working methods of Abderhalden, Dept. I, Part 2.1, page 979 ff., 1927) a 2,6-diaminoanthraquinone of the formula (II)
  • bis-acetamidoanthraquinones in particular bis-dimethylamino-acetylamino-anthraquinone and bis-hexamethyleneimino-acetylamino-anthraquinone, have antiviral properties. It was found to be surprising and unexpected that compounds of the general formula (I) in which R is hydrogen and R 2 is methyl or ethyl have now proven to be highly immunologically active substances.
  • the compounds obtained according to the invention were tested in the DTH test (delayed type hypersensitivity in mice) according to: Dietrich, F. M. & Hess, R.: Hypersensitivity in mice.
  • I Induction of contact sensitivity to oxazolone and inhibition by various chemical compounds. Int. Arch. Allergy 38, 2-4-6-251- (1970).
  • the data presented in the table below show the immune suppressive activity of the new compounds. Immunosuppression of 2,6-bis - / (methylamino) -acetylamino / - anthraquinone in comparison with cyclosporin-A
  • the new compounds show cytostatic activity in vivo and in vitro and are also proposed for the treatment of tumors and leukemic diseases in vertebrates.
  • the compounds obtainable according to the invention and their pharmacologically acceptable acid addition salts are active ingredients in pharmaceutical preparations.
  • the preparations intended for therapeutic purposes inhibit the rejection reaction of homologous grafts in mammals when given in amounts of 0.1 to 50 mg / kg body weight and day.
  • This dosage range can be adapted to achieve an optimal therapeutic effect; for example, several divided doses can be administered or the dose can be reduced according to the therapeutic situation.
  • a significant practical advantage is that these active ingredients can be administered in any way, e.g. B. orally, intraperitoneally, subcutaneously, intramuscularly or intravenously.
  • the active substances can be used alone or in combination with the usual pharmaceutical carriers. Suitable forms of use are e.g. B. tablets, capsules, suppositories, solutions, juices, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PCT/AT1985/000019 1984-08-01 1985-07-31 Nouveaux composes a l'activite immunisante Ceased WO1986000892A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT85903971T ATE41769T1 (de) 1984-08-01 1985-07-31 Immunwirksame verbindungen.
DE8585903971T DE3569107D1 (en) 1984-08-01 1985-07-31 Compounds having an immunizing activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT246884 1984-08-01
AT2468/84 1984-08-01

Publications (1)

Publication Number Publication Date
WO1986000892A1 true WO1986000892A1 (fr) 1986-02-13

Family

ID=3534897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT1985/000019 Ceased WO1986000892A1 (fr) 1984-08-01 1985-07-31 Nouveaux composes a l'activite immunisante

Country Status (8)

Country Link
US (1) US4794125A (enExample)
EP (1) EP0191058B1 (enExample)
JP (1) JPS61502891A (enExample)
AT (1) ATE41769T1 (enExample)
AU (1) AU4679985A (enExample)
DE (1) DE3569107D1 (enExample)
HU (1) HU197511B (enExample)
WO (1) WO1986000892A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000265A1 (en) * 1989-06-30 1991-01-10 Cancer Research Technology Ltd. Intercalating agents
WO1998025884A1 (en) * 1996-12-13 1998-06-18 Cancer Research Campaign Technology Limited Further anthraquinones with biological activity
WO1998025885A1 (en) * 1996-12-13 1998-06-18 Cancer Research Campaign Technology Limited Anthraquinones with biological activity

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI841500A0 (fi) * 1984-04-13 1984-04-13 Valtion Teknillinen Foerfarande foer uppbygnande av cellulolytiska jaeststammar.
US5766912A (en) 1986-03-17 1998-06-16 Novo Nordisk A/S Humicola lipase produced in aspergillus
TWI378792B (en) * 2008-04-02 2012-12-11 Nat Defense Medical Ct Synthesis, telomerase inhibition and cytotoxic studies on 2,7-disubstituted anthraquinone derivatives
CN111718276B (zh) * 2019-12-20 2021-03-30 南京晓庄学院 一种衍生物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859315A (en) * 1972-10-30 1975-01-07 American Home Prod Disubstituted acetamidoanthraquinones
FR2321881A1 (fr) * 1975-08-26 1977-03-25 Hoechst Ag 2,6-diamino-anthraquinones substituees, leur procede de preparation et leurs applications
DE2702137A1 (de) * 1976-01-22 1977-09-29 Rudolf Biber Verfahren zur herstellung neuer 2,6-bis-(aminoacylamino)-anthrachinone sowie ihrer saeureadditionssalze mit antiviraler bzw. interferoninduzierender eigenschaft

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859315A (en) * 1972-10-30 1975-01-07 American Home Prod Disubstituted acetamidoanthraquinones
FR2321881A1 (fr) * 1975-08-26 1977-03-25 Hoechst Ag 2,6-diamino-anthraquinones substituees, leur procede de preparation et leurs applications
DE2702137A1 (de) * 1976-01-22 1977-09-29 Rudolf Biber Verfahren zur herstellung neuer 2,6-bis-(aminoacylamino)-anthrachinone sowie ihrer saeureadditionssalze mit antiviraler bzw. interferoninduzierender eigenschaft

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000265A1 (en) * 1989-06-30 1991-01-10 Cancer Research Technology Ltd. Intercalating agents
WO1998025884A1 (en) * 1996-12-13 1998-06-18 Cancer Research Campaign Technology Limited Further anthraquinones with biological activity
WO1998025885A1 (en) * 1996-12-13 1998-06-18 Cancer Research Campaign Technology Limited Anthraquinones with biological activity

Also Published As

Publication number Publication date
JPS61502891A (ja) 1986-12-11
JPH0572903B2 (enExample) 1993-10-13
AU4679985A (en) 1986-02-25
EP0191058B1 (de) 1989-03-29
DE3569107D1 (en) 1989-05-03
EP0191058A1 (de) 1986-08-20
US4794125A (en) 1988-12-27
HU197511B (en) 1989-04-28
ATE41769T1 (de) 1989-04-15
HUT39150A (en) 1986-08-28

Similar Documents

Publication Publication Date Title
EP0152944A2 (de) Verwendung von Adenosin-Derivaten als Antiallergica und Arzneimittel, die diese enthalten
DE2165962C2 (de) 4-Hydroxy-6-arylpyrimidine
DE2528360A1 (de) Neue pyrimidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
EP0062199B1 (de) N-(4-Aminobenzoyl)-N'-benzylbispidin, seine Herstellung und dieses enthaltende Arzneimittel
WO1986000892A1 (fr) Nouveaux composes a l'activite immunisante
CH668970A5 (de) 5-pyrimidincarboxamide, die fuer die behandlung von leukaemie und tumoren verwendbar sind.
DE1815808B2 (de) 1 -(Alkanoylamiitophenoxy)-3-alkylamino-2-propanole deren Herstellungsverfahren und pharmazeutische Zusammensetzungen auf deren Basis
DE2604845A1 (de) Neue piperazinderivate
EP0122488B1 (de) Bis-(Piperazinyl- bzw. Homopiperazinyl)-Alkane
DE2713933C2 (enExample)
DE2405094A1 (de) 2-aminoindan-abkoemmlinge, deren herstellung und verwendung
DE3111593C2 (de) 3-Desoxy-3-[3-(2-chloräthyl)-3-nitrosoureido]-D-allopyranose, Verfahren zu ihrer Herstellung und diese Verbindung enthaltende Antitumormittel
DE1965711C3 (de) l^-Dihydro-133-triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE1963317A1 (de) Chemische Verfahren und Produkte
DE2455026C2 (enExample)
DD152334A5 (de) Verfahren zur herstellung von 1-(aminoalkylamino)-5,8-dihydroxy-4-substituierten-anthrachinonen
DE1695855B2 (de) 4-(5-Isobutyl-2-pyrimidinyl)-sulfonamidophenylessigsäure-(2-methoxy-5-Chloranilid) und dessen Salze mit physiologisch verträglichen Basen
DE69314794T2 (de) Komplex von 2-aminäthansulfonsäure und zink
DE3105122A1 (de) Neue piperazin-verbindungen, verfahren zu ihrer herstellung und ihre verwendung
DE69328357T2 (de) Komplex von 2-aminoäthansulfonsäure und zink
EP0196330B1 (de) Verwendung von pyrrothinderivaten
AT360043B (de) Verfahren zur herstellung von neuen 9-substi- tuierten purinen und deren salzen
DE3220185A1 (de) 4-amino-benzylamin-derivate, verfahren zu ihrer herstellung, sowie ihre verwendung als pharmazeutica
DE1443376C3 (de) Verfahren zur Herstellung von 2-Amino-alpha-substituierten Benzylidenaminen, sowie neue 2-Amino-alpha-substituierte Benzylidenamine als solche
DE2908032A1 (de) Acetale und hemiacetale von aminoaldehyden und diese enthaltende therapeutische zubereitungen

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU BG BR CH DE DK FI GB HU JP NL NO RO SE SU US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985903971

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1985903971

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1985903971

Country of ref document: EP